Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Imagence® 3.0, the latest version of the deep learning-based software that automates the analysis of high-content screening (HCS) imaging data. The release of the award-winning software features significant enhancements developed in close collaboration with leading partners in the biopharmaceutical industry who are using Genedata Imagence to automate complex HCS imaging workflows in order to scale up their R&D processes. Genedata Imagence 3.0 will be presented at the SLAS2021 Digital International Conference and Exhibition next week.
The latest enhancements include AI-based analytics that improve HCS result quality, including an innovative “uncertainty metric” that qualifies a deep learning-based classification model to enable automatic rejection of questionable results. Consequently, wastage of time and resources on following up spurious results is substantially reduced. Genedata Imagence now also automatically flags novel phenotypes (e.g. reflecting new, hitherto undiscovered modes of drug action), thus enabling scientists to focus their attention on new hypotheses generated by such a priori unexpected results. In combination with its innovative visualizations, Genedata Imagence 3.0 thus enables very rapid incorporation of new findings into already trained neural network models and the efficient (re-) analysis of other and larger high content screens.
As for other components of the Genedata Biopharma Platform, development of Genedata Imagence remains focused on supporting all leading HCS instruments, irrespective of technology vendor, and strengthening the comparability of results across different instruments, labs and sites. The software is designed to integrate easily with other enterprise software systems, offering full data capture options and image store integration within a full, smooth analysis workflow for screening applications, from raw data to pharmacological endpoints.
The full automation of image processing and simplified analysis workflows in Genedata Imagence shorten project cycles and do away with the need for extensive expert analysis customization. Images and results are available in real time and the scalable architecture guarantees the best possible performance at any time.
“The new features we have introduced in Genedata Imagence 3.0 illustrate our firm commitment at Genedata to automate as much as possible the analysis of HCS, a bottleneck in drug discovery,” noted Othmar Pfannes, Ph.D., CEO of Genedata. “It’s also proof of our focus on helping our customers to speed up their R&D processes, reducing costs due to poor data quality and enabling efficient collaboration within a highly challenging domain.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.